Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Phys Vivascardiovascular

Phys Vivas · cardiovascular

Cardiovascular Prevention and Rehabilitation — Viva Defence

Structured DCE viva for cardiovascular prevention: long-case defence of a 62-year-old post-NSTEMI patient with statin-associated muscle symptoms — the secondary prevention bundle defended, the SAMS protocol, and rehabilitation adherence.

4 min readVerification in progress

Target exams

FRACP DCEMRCP Part 2
On this page
Study tools

Target exams

FRACP DCEMRCP Part 2
Prompt
Structured DCE viva for cardiovascular prevention: long-case defence of a 62-year-old post-NSTEMI patient with statin-associated muscle symptoms — the secondary prevention bundle defended, the SAMS protocol, and rehabilitation adherence.

Opening statement (SASPOP, delivered aloud)

"Mr Halloran is a 62-year-old man four months into recovery from an NSTEMI treated with a drug-eluting stent to the LAD. His main problems are: established secondary-prevention pharmacotherapy now partly self-ceased, with statin-associated muscle symptoms that need structured assessment; ongoing smoking, the single largest modifiable driver of his next event; non-attendance at cardiac rehabilitation, which forfeits a mortality-reducing intervention; and an information problem — he is making decisions from internet material rather than from a conversation with us. I would like to restore the full secondary prevention bundle using a validated statin protocol, engage him with rehabilitation and smoking cessation, and rebuild his trust in the plan." [1] [5]

Physician Medicine Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Physician Medicine fellowship library.

Sign in to continueSee pricing
References7ShowHide
  1. [1]Nelson MR, Banks E, Brown A, et al. 2023 Australian guideline for assessing and managing cardiovascular disease risk Med J Aust, 2024.PMID 38623719
  2. [2]Wood FA, Howard JP, Finegold JA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects N Engl J Med, 2020.PMID 33196154
  3. [3]Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes N Engl J Med, 2015.PMID 26039521
  4. [4]Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients N Engl J Med, 2023.PMID 36876740
  5. [5]Anderson L, Oldridge N, Thompson DR, et al. Exercise-based cardiac rehabilitation for coronary heart disease Cochrane Database Syst Rev, 2016.PMID 26730878
  6. [6]Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet, 2005.PMID 16214597
  7. [7]Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome N Engl J Med, 2018.PMID 30403574
Physician Medicine Pro

$29/ monthor $279 / year

The complete Physician Medicine library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousCardiomyopathies — Viva DefencecardiovascularNextCoronary Artery Disease — Viva Defencecardiovascular